Every AXLRx IgA Nephropathy report, across 9 report types and 3 markets. Each is scoped to your asset and verified to a live source.
From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.
How US payers gate the five FDA-approved IgAN therapies — biopsy, proteinuria and RAS-blockade step-through, the Filspari REMS, Part D routing and the ICER 2026 assessment.
US IgA nephropathy epidemiology, the biopsy-and-proteinuria diagnostic gate, and the shift from RAS-blockade supportive care to five disease-modifying therapies.
Novel IgAN agents are newly registered across the GCC but not yet formulary-listed — nephrology specialist centres and the private hospital market are the fastest access channel while biopsy capacity limits diagnosis.
Binding constraint: eGFR-confirmed evidence beats a second accelerated approval on UPCR surrogate data alone.
Why NICE will reject any IgAN submission that isn't built on eGFR slope with mandatory SGLT2i background, the 3,000-5,000 UK patients eligible for a novel agent, and the ESRD-delay cost model that clears the QALY bar.
The Renal Association's IgAN guideline committee, not any single physician, sets the clinical reference point NICE checks technology appraisals against. This workbook sizes that committee and the network behind it before individual outreach begins.
GCC IgA nephropathy expertise concentrates in five named tertiary centres and roughly 300 practicing nephrologists, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it.
No novel IgA nephropathy agent is SFDA-registered in the GCC — first-mover filing, not clinical differentiation, decides which drug becomes the de-facto standard.
NICE's accepted cost-effectiveness case for budesonide (TA937, updated by TA1128) rests on a 5–8 year modelled ESRD delay, and the same mandatory ACEi/ARB gate applied to sparsentan narrows the UK's eligible IgA nephropathy population from 10,000–15,000 to 3,000–5,000 patients.
UK Renal Registry data, the ACEi/ARB-first Renal Association pathway, and the NHS economic case for novel agents built on £40–50M annual ESRD cost.
Why IgA nephropathy has no NPHC programme at all — access runs entirely through hospital pharmacy committees or private insurance, gated by a biopsy available at fewer than 20 GCC centres.
A GCC nephrology network capacity survey estimates 8,000-12,000 IgA nephropathy patients across the region, but the same survey finds kidney biopsy performed in fewer than 30% of eligible proteinuric patients, and zero patients are on any SFDA-registered novel agent as of 2024.
IgAN diabetes-masking effect, the kidney biopsy bottleneck, and the ESRD progression gap across GCC nephrology practice.
An estimated 8,000-12,000 GCC IgAN patients narrow to fewer than 30% ever biopsied, then to zero on novel therapy, since no agent is SFDA-registered as of 2024. The funnel gap, not the prevalence estimate, is what a GCC patient flow model has to size.
150,000 US IgA nephropathy patients, of whom 70,000-90,000 are biopsy-confirmed. Only 5,000-8,000 are on novel therapy today, while 15,000-25,000 patients with UPCR above 1g/g remain the addressable high-risk cohort this model sizes precisely.
10,000-15,000 UK IgA nephropathy patients, of whom approximately 8,000 are tracked in the UK Renal Registry. Only 3,000-5,000 clear the mandatory ACEi/ARB and SGLT2i optimisation gate to become eligible for a novel agent, and fewer than 500 currently access one pre-NICE.
All five FDA-approved IgAN therapies clear the same prior-authorization gate, biopsy-confirmed diagnosis, UPCR 0.8-1.5 g/g, eGFR 30 or higher, RAS-blockade step-through, rather than a negotiated rebate table. No formal net-price data exists because access here runs on step-therapy criteria, not payer negotiation.
NICE accepted an eGFR-slope-to-ESRD-delay model, not the headline proteinuria reduction, as the value basis for budesonide (TA937, expanded by TA1128) and sparsentan (TA1074) in IgA nephropathy. The mandatory ACEi/ARB and SGLT2 inhibitor optimisation gate narrows the UK's 10,000 to 15,000 patients to a 3,000 to 5,000 novel-agent-eligible pool before that pricing math applies.
IgA nephropathy sits outside NPHC's genetic/orphan disease scope entirely, so there is no GCC formulary price to model. Budesonide clears case-by-case at SAR 80,000-120,000/year through hospital committees or private insurance; sparsentan is not yet tender-priced at all.
NICE's accepted 20-35% PAS discount off budesonide's WAC sets the pricing floor sparsentan already clears too, against a £140-180M NHS budget ceiling once the ACEi/ARB gate narrows eligibility to 3,000-5,000 patients.
An estimated 150,000 Americans have IgA nephropathy, but only 70,000-90,000 are biopsy-confirmed and just 5,000-8,000 are on a disease-specific therapy today, within a 15,000-25,000-patient high-risk eligible cohort.
The UK Renal Registry actively tracks about 8,000 IgA nephropathy patients against an estimated 10,000-15,000 total prevalence; only 3,000-5,000 are eligible for a novel agent, and fewer than 500 currently receive one.
Two novel agents in Named Patient access ahead of NICE decisions — and the £20,000-30,000/QALY standard threshold both must clear, since IgAN doesn't qualify for the ultra-rare HST track.
AXLRx publishes Competitive Intelligence, Payer & HTA, Disease Landscape, Launch Readiness, KOL Mapping, Market Sizing Model, Patient Flow Model, Pricing Strategy Model, and HTA Strategy Model for IgA Nephropathy. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current IgA Nephropathy coverage spans United States, GCC (Gulf), and United Kingdom. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest IgA Nephropathy reports were updated July 2026.